+34 914 524 941    info@algenex.com

CrisBioTM

For decades, the vaccines have been produced in cell cultures or fertile eggs. The huge demand of vaccines and the urgent need to reduce the vaccine production costs, to make them accessible to the whole human population and farm animals, made crucial the development of new production processes. Insects possesses unique features for recombinant protein production.

 

ALGENEX has developed and patented this innovative technology platform, which take advantage of a multicellular living organism, the Lepidoptera Trichoplusia ni (T. ni ). This highly efficient technology combines T. ni chrysalises with the proprietary improved baculovirus vectors TopBac® for the production of recombinant subunit vaccines. The ALGENEX’ scientific team has optimized and industrialized CrisBioTM technology, reaching production yields that exceed 20 times the productivity of insect cells cultured in bioreactors.

CONVENTIONAL

TOP-BAC-process
flecha

DREAM

crisbio-dream
flecha

REALITY

crisbio-reality

CONVENTIONAL

TOP-BAC-process
flecha

DREAM

crisbio-dream
flecha

REALITY

crisbio-reality
In some aspects, the production platform CrisBioTM is similar to the egg-based production, but differs in its versatility. Eggs can be used only for viruses that replicate efficiently in them. Frequently, a single vaccine dose is obtained from a single egg (e.g. influenza vaccine). In contrast, the T. ni pupae  may  produce any recombinant subunit vaccine and dozens of vaccine doses can be produced by a single baculovirus infected pupa. CrisBioTM  technology consist in a semi-automated process which facilitates scaling-up production. Several companies produce today their next generation vaccines by this technology.
crisbio-biocapsule
Download CrisBio flyer
Download CrisBio flyer